Skip Navigation

COVID-19 Update

Due to interest in the COVID-19 vaccines, we are experiencing an extremely high call volume. Please understand that our phone lines must be clear for urgent medical care needs. We are unable to accept phone calls to schedule COVID-19 vaccinations at this time. When this changes, we will update this website. Our vaccine supply remains limited. Read all COVID-19 Vaccine Information.

Patient Care Options | Visitor Guidelines | Coronavirus Information | Self-Checker | Get Email Alerts

The Sidney Kimmel Comprehensive Cancer Center

The Bloomberg~Kimmel Institute for Cancer Immunotherapy

About the Institute"Immunotherapy is a game changer. We believe that a patient's own immune system can ultimately beat any cancer." The Bloomberg-Kimmel Institute for Cancer Immunotherapy

Learn More About Immunotherapy

 
Fast Facts
About BKI
2016

BKI was established in 2016, in response to then-Vice President Joe Biden's Cancer Moonshot initiative.

$125M

The institute was founded with a $125 million philanthropic investment from benefactors Michael R. Bloomberg and Sidney Kimmel and more than a dozen other supporters.

10%

We believe research has harnessed only 10 percent of the immune system's potential ability to fight cancer. We want to realize its full potential.

Our Mission
Take the science to a new level.

With so much left to discover, the future of immunotherapy may stem from emerging areas of science that are underappreciated and not easily funded by conventional means. We will invest in these promising scientific programs.

Develop powerful new technologies.

We will build on immunotherapy's momentum with new technologies that allow us to study the tumor microenvironment thoroughly and efficiently, and seek to understand why immunotherapy works for some patients and not others.

Translate research into therapies more rapidly.

The need for effective cancer treatments is urgent, but it takes many, many years to bring a concept from the lab to the patient. We are accelerating the clinical development process by offering small, cutting-edge clinical trials supported by an immense translational research team.

""
Our Approach
A Collaboration of Scientific and Clinical Specialties

We support cancer immunology research across many cancer types.

We emphasize research aimed at impacting cancer care and clinical trials. Our multidisciplinary team is probing the vast potential of the immune system.

We are developing precision-based approaches that treat genetic subsets of cancer patients with the specific immunotherapy — or a combination of immunotherapy and other treatments — most likely to succeed.

The Strength of Giving
Meet Our Founding Donors

The Bloomberg-Kimmel Institute for Cancer Immunotherapy was founded in large part with gifts from two longstanding Johns Hopkins champions: Michael R. Bloomberg and Sidney Kimmel.

Read about our donors and what drives their philanthropy.
image of Michael R. Bloomberg
Michael R. Bloomberg
image of Sidney Kimmel
Sidney Kimmel
Related Reading
02/12/19
How Viagra Puts A Brake on A Master Growth Regulator to Treat Heart Disease
Findings have implications for heart failure, but also for cancer, diabetes and autoimmune disorders
07/31/18
Turning Off Protein Could Boost Immunotherapy Effectiveness on Cancer Tumors
Researchers diiscovered inhibiting a protein could reduce tumor burdens and enhance the effectiveness of immunotherapy treatments
04/16/18
Drug Reduces Size of Some Lung Cancer Tumors, Relapse Rate After Surgery
The research teams discovered new infiltration of immune cells into the lung cancer after nivolumab, an anti-PD-1 drug, was administered.
back to top button